Abstract
Neonatal neuroblastoma accounts for less than 5% of all cases of neuroblastoma but carries a favorable prognosis with most patients being stratified into low- or intermediate-risk groups for recurrence of disease. The epidemiology of neonatal (age less than 30 days) neuroblastoma contrasts greatly with patients older than 30 days. Owing to the unique potential for spontaneous regression of this tumor type, several groups have sought to reduce therapy given to neonates with neuroblastoma and use a watch-and-wait approach for many low-risk patients. Ongoing studies also seek to reduce therapy for some intermediate-risk patients in an attempt to lessen exposure to surgical intervention and cytotoxic chemotherapy. In this review, we discuss the epidemiology, clinical presentation, staging, and treatment for neonates with neuroblastoma.
Keywords: Neuroblastoma, neonatal, regression.
Current Pediatric Reviews
Title:Current Management of Neonatal Neuroblastoma
Volume: 11 Issue: 3
Author(s): Rodrigo B. Interiano and Andrew M. Davidoff
Affiliation:
Keywords: Neuroblastoma, neonatal, regression.
Abstract: Neonatal neuroblastoma accounts for less than 5% of all cases of neuroblastoma but carries a favorable prognosis with most patients being stratified into low- or intermediate-risk groups for recurrence of disease. The epidemiology of neonatal (age less than 30 days) neuroblastoma contrasts greatly with patients older than 30 days. Owing to the unique potential for spontaneous regression of this tumor type, several groups have sought to reduce therapy given to neonates with neuroblastoma and use a watch-and-wait approach for many low-risk patients. Ongoing studies also seek to reduce therapy for some intermediate-risk patients in an attempt to lessen exposure to surgical intervention and cytotoxic chemotherapy. In this review, we discuss the epidemiology, clinical presentation, staging, and treatment for neonates with neuroblastoma.
Export Options
About this article
Cite this article as:
B. Interiano Rodrigo and M. Davidoff Andrew, Current Management of Neonatal Neuroblastoma, Current Pediatric Reviews 2015; 11 (3) . https://dx.doi.org/10.2174/1573396311666150714105220
DOI https://dx.doi.org/10.2174/1573396311666150714105220 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Targeting Translation for Treatment of Cancer - A Novel Role for IRES?
Current Cancer Drug Targets Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Current Pharmaceutical Design Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Neurodegenerative Pathways in Alzheimer’s Disease: A Review
Current Neuropharmacology Classification of Sarcomas Using Bioinformatics and Molecular Profiling
Current Pharmaceutical Biotechnology Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Listeria monocytogenes as a Vector for Anti-Cancer Therapies
Current Gene Therapy Polypharmacology of Approved Anticancer Drugs
Current Drug Targets Procathepsin D as a Tumor Marker, Anti-Cancer Drug or Screening Agent
Anti-Cancer Agents in Medicinal Chemistry CD248: Reviewing its Role in Health and Disease
Current Drug Targets Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Recent Patents on Anti-Cancer Drug Discovery Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Molecule of the Month
Current Topics in Medicinal Chemistry The Relevance of Supplemental Vitamin D in Malignancies
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets Small-Animal Molecular Imaging for Preclinical Cancer Research: μPET and μSPECT
Current Radiopharmaceuticals Establishment of Cholinergic Neuron-like Cell Lines with Differential Vulnerability to Nitrosative Stress
Current Neurovascular Research